Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Empowering Hispanic Patients' Lung Cancer Screening Uptake (Empower Latinx)
NCT06225414 · View on ClinicalTrials.gov ↗
Study Summary
The Hispanic/Latinx community (hereafter Hispanic) is the country's second-largest racial/ethnic group, accounting for 19.1% of the total population. However, they remain one of the most underserved populations with suboptimal access to healthcare and screening services due to low income, lack of health insurance, perceived discrimination, language barriers, and limited health literacy. Lung cancer is the leading cause of cancer related mortality with 1.8 million annual deaths worldwide, with Hispanic patients known to have lower survival rates compared with non-Hispanic whites. Lung cancer screening (LCS) with low dose computed tomography (LDCT) decreases this mortality rate of lung cancer by 20%. Yet many Latinx patients who are eligible for lung cancer screening are still falling through the cracks which prevents patients the ability to detect lung cancer early. This study will test and compare the effect of a multi-level intervention on ordering LDCT within 4 months after patient enrollment to those in an Enhanced Usual Care. Our proposed intervention includes: * Primary care provider notifications of patients' LCS eligibility; * Patients' education; * Patients' referral to financial navigation resources; * Patients' reminder to discuss LCS during primary care provider (PCP) visit.
Conditions Studied
Interventions
- OTHER Usual Care
- BEHAVIORAL Patient education
- BEHAVIORAL Brief Patient Education
- BEHAVIORAL Referral to financial navigation resources
- BEHAVIORAL Patient Reminders
Study Locations (10)
California
- UCI Health Family Health Center - Anaheim — Anaheim
- UCI Health-Costa Mesa — Costa Mesa
- UCI Health-Irvine — Irvine
- UCI Health-Laguna hilla — Laguna Hills
- UCI Health-Newport — Newport Beach
- UCI Health SeniorHealth Center -Pavillion 4 — Orange
- UCI Medical Center, Pavilion 3 — Orange
- UCI Health Family Health Center - Santa Ana — Santa Ana
- UCI-Health Tustin — Tustin
- UCI Health-Yorba Linda — Yorba Linda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-02-12 |
| Est. Completion | 2026-02 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06225414
The ClinicalTrials.gov registry entry for NCT06225414 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 353 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 5 interventions — of which Usual Care is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06225414 reports 10 study locations spanning 1 distinct geographic area — top geographies include California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06225414 about?
NCT06225414 is a clinical study titled "Empowering Hispanic Patients' Lung Cancer Screening Uptake (Empower Latinx)". The Hispanic/Latinx community (hereafter Hispanic) is the country's second-largest racial/ethnic group, accounting for 19.1% of the total population. However, they remain one of the most underserved populations with suboptimal access to healthcare and screening services due to low income, lack of he...
What is the current status of trial NCT06225414?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2024-02-12. Estimated completion is 2026-02.
What conditions does trial NCT06225414 study?
This clinical trial studies the following conditions: Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06225414?
The interventions under investigation include: Usual Care (OTHER), Patient education (BEHAVIORAL), Brief Patient Education (BEHAVIORAL), Referral to financial navigation resources (BEHAVIORAL), Patient Reminders (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06225414?
This trial is sponsored by University of California, Irvine, which has 353 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06225414 being conducted?
This trial has 10 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.